The Future Roadmap for AI & Generative AI in Life Sciences
27th March, 3pm GMT
Join our panel of experts on 27th March at 3 pm UK time for an engaging discussion on how Artificial Intelligence (AI) and Generative AI are set to revolutionize the life sciences industry. This webinar will explore how these cutting-edge technologies can accelerate innovation, enhance productivity, drive digital transformation, improve patient centricity, streamline operations, and provide a competitive edge in the market.
Key Topics
Accelerating Breakthroughs
: Discover how trustworthy AI can drive innovation at every stage of the pharmaceutical life cycle.
Generative AI Use Cases
: Explore the potential of Generative AI in life sciences, including applications of synthetic data, digital twins, and the integration of expansive language models.
Reliable Insights in a Regulated Environment
: Learn how to gain transparent, valid, and actionable insights while navigating the complexities of a highly regulated industry
Speakers:
Olivier Bouchard, Global Senior Advisory - AI Health and Life Science Lead, SAS France
Olivier Bouchard is an Industry Advisor based in France, Paris and is part of the Health and Life Sciences Practice at SAS. He has been at SAS for several years with over 20+ years in the pharmaceutical industry, supporting various software solutions. Olivier is a strong believer in the power of AI and Analytics and enjoys transforming Life Sciences and Healthcare markets with insights derived from data. He is also an active member of the Lifescience EMEA GTM team to ensure consistent branding and messaging accross Lifescience accounts.
Dr Ann Beliën, Founder & CEO of Rejuvenate Biomed
As founder and CEO of Rejuvenate Biomed, she has transformed the company from a discovery start-up into a clinical-stage enterprise supported by international investors and a team of 24 experts, driving our mission to develop safe combination drugs for age-related diseases. Dr. Belien brings over 25 years of drug development experience, primarily gained at Johnson and Johnson Pharmaceutical companies from bench to market, including expertise in due diligence, company integration, and open innovation to her current role.
Philippe Marc, Global Head of Integrated Data Sciences, Novartis Biomedical Research
At Novartis, my role is to maximize the impact of data on our research pipeline's speed and success rate. I work with the Biomedical Research Computational Science Council to develop a global data-driven strategy for R&D. Last few years, I have led the writing of our Biomedical Research Data Strategy, co-led the definition of our data42 Clinical platform, contributed to our Enterprise Data Management; and driven our Generative AI prototyping. My team's primary focus is to shape and mine data to aid in the selection of the best compounds and companion biomarkers/diagnostics. We combine data from clinical and pre-clinical studies with multi-omics, digital devices, and imaging data, and apply Machine Learning/AI/GenAI techniques to those Data Products. Our goal is to design better drugs with fewer side effects using data-powered Translational Medicine. Outside of Novartis, I serve as an advisor and lecturer, giving back to the educational community that has supported me.
Faisal Khan, Corporate Vice President AI and Analytics, Novo Nordisk
Faisal M. Khan, Ph.D. is the Corporate Vice President for Artificial Intelligence and Analytics at Novo Nordisk. His team focuses on the applications of AI and data science throughout the drug development lifecycle. His interests focus on the intersections of data science, digital health, biostatistics, bioimaging, personalized medicine, and healthcare delivery. His career has encompassed all aspects of healthcare and biomedicine, including diagnostics, devices, clinical trials/therapeutics, and payers/insurance. Dr. Khan has worked or consulted across academia and industry with both startups and Fortune-50 companies. He has over 100 published papers, abstracts, and patents on the applications of machine learning and artificial intelligence for healthcare and the life sciences.
Pascal Bouquet, HealthtechPartners 42